MedPath

Comparison of the effects of the two drugs dexmedetomidine and midazolam when given for spinal anaesthesia

Not yet recruiting
Conditions
Patients with major co-morbid conditions
Registration Number
CTRI/2018/03/012353
Lead Sponsor
Dr J Jancy
Brief Summary

Spinal anaesthesia is the commonly employed anaesthetic technique for lower limb surgeries. But it’s limitation is short duration of analgeisa. In order to extended the duration of block a number of agents are added along with local anaesthetic for spinal anaesthesia. Dexmedetomidine and midazolam are two such additives for spinal anaesthesia. In the present study we intend to compare dexmedetomidine and midazolam when added to spinal anaesthesia with 0.75% ropivacaine spinal anaesthesia.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
88
Inclusion Criteria
  • 1)Age 18-60 years.
  • 2)American Society of Anaesthesiologists (ASA) Grade I and II.
Exclusion Criteria

1)Patient refusal for subarachnoid block 2)Known allergy to the study drugs 3)Infection at the puncture site 4)Coagulation disorders 5)Neurological disorders 6)Hepatic and renal disorders 7)Use of antipsychotic medications 8)Body mass index ≥ 30kg/m2 9)Pregnancy & lactation 10)ASA ≥ III.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Onset and duration of sensory and motor block1)Onset of motor and sensory block will be assessed every 3min for the first 15 min after spinal anaesthesia. | 2) Duration of motor and sensory block will be assessed at the end of surgery in the post operative period.
Secondary Outcome Measures
NameTimeMethod
Haemodynamic stabilityDuration of analgesia

Trial Locations

Locations (1)

Ramaiah Medical College Hospital

🇮🇳

Bangalore, KARNATAKA, India

Ramaiah Medical College Hospital
🇮🇳Bangalore, KARNATAKA, India
Dr J Jancy
Principal investigator
9080112470
jancyjoseph0601@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.